Dr. Reddy’s and OneSource agree not to sell Novo Nordisk’s anti-obesity drug in India amid patent infringement lawsuit.

Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA.Weight loss injections have become incredibly popular in the ...

MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...

GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Our most-read articles explore “occlusion MI” versus STEMI, TAVI in asymptomatic AS, and highlights from recent conferences.

The Delhi High Court declined to stop Dr. Reddy’s from manufacturing Novo Nordisk’s drug, but will continue to hear the ...

More than one million adults in Florida are using injectable GLP-1 drugs to fight obesity—making the state one of the largest ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...